news

ViraTherapeutics raises €3.6 million to advance its lead product VSV-GP

Posted: 24 June 2015 | Victoria White

ViraTherapeutics has announced the first closing of a Series A financing round, raising €3.6 million that it will use to advance its lead product VSV-GP…

ViraTherapeutics has announced the first closing of a Series A financing round, raising €3.6 million.

The round was co-led by Boehringer Ingelheim Venture Fund (BIVF) and EMBL Ventures, and included an investment from Austria Wirtschaftsservice (aws) through its Venture-Capital-Initiative.

ViraT will use these funds to advance its lead product VSV-GP through preclinical studies prior to clinical Phase 1b testing to demonstrate early clinical proof of concept. ViraT expects to start its first clinical trials with VSV-GP in cancer patients in 2017.

 

Reserve your FREE place

 


Are low affinity or poor TCR yields slowing you down?

Explore how CHO expression of soluble TCRs and TCR affinity maturation workflows via phage, serving as essential building blocks for early-stage TCR-TCE candidate generation.

22 October 2025 | 16:00 PM BST | FREE Webinar

Join Jiansheng Wu, Ph.D. to explore two integrated strategies:

  • High-titer CHO-based expression of sTCRs (~100 mg/L), enabling scalable and high-throughput production
  • Optimized phage display affinity maturation, improving TCR binding by up to ~10,000-fold

Whether you’re starting a new TCR program or optimizing an existing platform, this session will offer actionable strategies to accelerate discovery and improve candidate quality.

Register Now – It’s Free!

 

VSV-GP is a highly potent oncolytic virus that carries the surface protein from the lymphocytic choriomeningitis virus (LCMV). VSV-GP, due to this LCMV pseudo-typing could be the first oncolytic virus therapeutic to be administered systemically on a repeated basis without its cancer killing properties being inactivated by the patient’s immune system.

VSV-GP replicates specifically and rapidly in tumour cells resulting in their destruction. This results in a profound local immunisation effect that further enhances the effectiveness of VSV-GP. Based on its unique characteristics, VSV-GP has significant potential in the immuno-oncology space either as a stand-alone agent or in combination with other treatment options.

VSV-GP is the only viral vector system that effectively boosts itself

Professor Dorothee von Laer, Founder, Chief Scientific Officer of ViraT and the inventor of VSV-GP, said, “This round of financing will allow us to take VSV-GP into the clinic where we hope to demonstrate that this unique oncolytic viral therapeutic can deliver important benefits to patients with solid tumours.”

“To my knowledge VSV-GP is the only viral vector system that effectively boosts itself, enabling it to evade neutralization by auto-drug antibodies upon repeated administration. These properties are expected to allow ground-breaking application of VSV-GP in tumour therapy, either in combination with other immuno-oncology principles or via in cis expression of antibodies, cytokines and tumour-associated antigens by VSV-GP itself,” said Dr Detlev Mennerich, Investment Director at BIVF.

Dr Jan Adams, a Managing Director at EMBL Ventures, added, “ViraT’s VSV-GP clearly stands-out in the exciting immuno-oncology space given it could be the first oncolytic viral treatment with the ability to be administered systemically on multiple occasions. This is a key differentiator and is expected to make a significant difference to the treatment benefits it could deliver to cancer patients.”

 

Related topics

Related organisations